-
CD36 Lipid Signaling Drives Immune Escape in AML
2026-09-28
Guo et al. identify a CD36-dependent pathway in which oxidized LDL and palmitate cooperate to activate innate immune signaling in acute myeloid leukemia cells and suppress T-cell responses. The study links this mechanism to reduced decitabine efficacy in experimental models and reports that statin-mediated lipid restriction can improve treatment response, while leaving clinical benefit to be tested.
-
MiR-24-3p in Doxorubicin-Related Heart Failure
2026-09-27
This study connects increased miR-24-3p with suppression of Sp1 and PI3K signaling in doxorubicin-induced heart failure, using rat and H9c2 cell models to test the relationship. Its gain- and loss-of-function results support miR-24-3p as a candidate regulator of cardiac injury, while leaving important questions about pathway mechanism and clinical relevance open.
-
IWP-2 Workflow for Wnt Production Inhibition
2026-09-26
IWP-2 blocks Porcupine-dependent Wnt production, making it useful for testing whether a cellular phenotype depends on secreted Wnt rather than only downstream pathway activity. This guide connects its reported MKN28 cancer-cell findings to practical dosing, controls, and troubleshooting—while distinguishing those data from a developmental-neuroscience reference study that informs experimental design, not IWP-2 biology.
-
5-(N,N-dimethyl)-Amiloride in Endothelial Research
2026-09-26
Use 5-(N,N-dimethyl)-Amiloride hydrochloride to test how Na+/H+ exchange and intracellular pH regulation shape endothelial injury readouts—without confusing this pathway perturbation with the moesin mechanism reported in sepsis research. The article outlines a practical cell-based workflow, controls, and troubleshooting steps for pairing NHE inhibition with barrier and pH assays.
-
Berberrubine and Vitamin K Cycling in Thrombosis
2026-09-25
A mouse study combined non-targeted metabolomics, coagulation measurements, and molecular docking to investigate how berberrubine hydrochloride affects carrageenan-induced thrombosis. Its findings connect the antithrombotic phenotype with vitamin K-cycle-related pathways and nominate VKOR and GGCX as candidate targets, while leaving direct target validation and clinical relevance unresolved.
-
Irinotecan (CPT-11): From Mechanism to Translation
2026-09-25
Irinotecan is more than a topoisomerase I inhibitor: its value in colorectal cancer research depends on how well experiments capture prodrug activation, DNA damage, response heterogeneity, and tolerability. This article outlines a translational framework for using CPT-11 in cell and xenograft studies, with practical guidance for model selection, assay design, and interpretation.
-
10058-F4: c-Myc-Max Assay Guide
2026-09-24
A practical guide to using 10058-F4 C-Myc-Max dimerization inhibitor (SKU A1169) in viability, apoptosis, and acute myeloid leukemia research. It covers mechanism, model selection, stock preparation, cautious interpretation, and supplier evaluation without treating one assay readout as proof of target engagement.
-
Clasto-Lactacystin β-lactone and RIPK3 Turnover
2026-09-24
Clasto-Lactacystin β-lactone can help researchers test whether proteasomal activity contributes to loss of RIPK3 during infection. This article connects a landmark viral immune-evasion finding to practical assay controls, interpretation limits, and experimental design choices.
-
MLN8237 (Alisertib): Assay Scenarios
2026-09-23
A scenario-based guide to using MLN8237 (Alisertib), SKU A4110, in cell viability, proliferation, cytotoxicity, and mechanism-resolved assays. It connects Aurora A potency, formulation, apoptosis readouts, mitotic biomarkers, and practical vendor-selection criteria to improve experimental interpretation.
-
N3-kethoxal Workflows for RNA and DNA Mapping
2026-09-22
N3-kethoxal converts transient guanine accessibility in RNA and single-stranded DNA into an azide handle for downstream click readouts. This guide distinguishes structure mapping, cellular accessibility profiling, and R-loop-focused assays so researchers can select appropriate controls and avoid overinterpreting probe signals.
-
CD36 Lipid Signaling and Immune Escape in AML
2026-09-22
Guo et al. identify a non-canonical CD36 lipid-sensing program that enables acute myeloid leukemia cells to suppress T-cell activity and resist decitabine therapy. The study separates this immune mechanism from lipid oxidation and shows that lipid restriction with statins can improve hypomethylating-agent responses in experimental AML models.
-
EZ Cap™ Mouse IL-7 mRNA: R1054
2026-09-21
EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag), SKU R1054, is a cataloged mouse interleukin-7 mRNA reagent with an N1-methylpseudouridine designation and an HA-tag designation. Its molecular rationale is compatible with nucleoside-modified mRNA expression studies, but product-specific dose, formulation, sequence, delivery, and efficacy parameters require confirmation from the product documentation and pilot experiments.
-
ZIF8 Nanotheranostics for Ultrasound-Guided TNBC Therapy
2026-09-21
Li et al. developed a folic acid–PEG-functionalized ZIF8 nanoplatform that delivers Ciprofloxacin for ultrasound-guided, synergistic treatment of triple-negative breast cancer. The study links pH-responsive delivery with sonodynamic therapy, immunogenic cell death, immune activation, and ultrasound imaging, while also identifying important limitations for translation and experimental replication.
-
Cheminformatics for Optimized Small-Molecule Libraries
2026-09-20
Moret et al. developed a data-driven framework for comparing and designing focused small-molecule libraries using target coverage, selectivity, phenotype, chemical structure, clinical status, and user-defined priorities. The resulting LSP-OptimalKinase and LSP-MoA collections show how computational optimization can improve library compactness and biological reach before experimental screening.
-
Cefotaxime Workflows for Resistance Research
2026-09-19
Cefotaxime connects beta-lactam activity testing with plasmid-mediated resistance, bacterial infection models, and antimicrobial screening. This practical guide explains how to build reproducible assays, interpret results alongside carbapenemase data, and troubleshoot stability or selection problems.